Biopharmx (BPMX) Trading Down 7.7%
Biopharmx Corp (NYSEAMERICAN:BPMX) dropped 7.7% during trading on Monday . The stock traded as low as $0.11 and last traded at $0.12. Approximately 3,014,200 shares traded hands during mid-day trading, an increase of 103% from the average daily volume of 1,487,068 shares. The stock had previously closed at $0.13.
BPMX has been the subject of several analyst reports. HC Wainwright reiterated a “buy” rating and issued a $3.00 price objective on shares of Biopharmx in a research note on Wednesday, September 13th. Maxim Group decreased their price objective on shares of Biopharmx from $3.00 to $1.50 and set a “buy” rating for the company in a research note on Wednesday, September 13th.
Biopharmx (NYSEAMERICAN:BPMX) last released its quarterly earnings data on Wednesday, September 13th. The biotechnology company reported ($0.06) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.06). Biopharmx had a negative net margin of 22,005.88% and a negative return on equity of 5,749.08%. The business had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.02 million.
In related news, Director Stephen Morlock acquired 330,000 shares of the company’s stock in a transaction dated Friday, November 24th. The stock was bought at an average cost of $0.15 per share, with a total value of $49,500.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Vivo Capital Viii, Llc sold 296,394 shares of Biopharmx stock in a transaction on Thursday, November 9th. The stock was sold at an average price of $0.20, for a total transaction of $59,278.80. The disclosure for this sale can be found here.
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.